Deposition and biokinetics of inhaled nanoparticles.
Geiser M, Kreyling WG. · 2010
Read Deposition and biokinetics of inhaled nanoparticles. by Geiser M, Kreyling WG. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2826283.txt.
Introduction
Geiser and Kreyling reviewed in 2010 what happens to nanoparticles after they are breathed in, comparing their fate with that of particles a thousand times larger. Knowing where inhaled particles land, linger, and travel is the first step in judging their hazard, yet engineered nanoparticles behave unlike the bulk materials they are made from.
The review covers landing chances in the airways and how long particles stay. It also tracks the routes by which some cross into the blood and pile up in other organs before the body clears them. Whole-body measures give dose estimates for safety testing, while microscope work at single-particle level shows which cells and cell parts actually meet the particles. Real-world dose numbers anchor the whole account.
Catalog record
| CREATOR | Geiser M, Kreyling WG. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Deposition and biokinetics of inhaled nanoparticles By Marianne Geiser, Wolfgang G Kreyling Published in: Particle and Fibre Toxicology DOI: 10.1186/1743-8977-7-2 ABSTRACT Particle biokinetics is important in hazard identification and characterization of inhaled particles. Such studies intend to convert external to internal exposure or biologically effective dose, and may help to set limits in that way. Here we focus on the biokinetics of inhaled nanometer sized particles in comparison to micrometer sized ones. The presented approach ranges from inhaled particle deposition probability and retention in the respiratory tract to biokinetics and clearance of particles out of the respiratory tract. Particle transport into the blood circulation (translocation), towards secondary target organs and tissues (accumulation), and out of the body (clearance) is considered. The macroscopically assessed amount of particles in the respiratory tract and secondary target organs provides dose estimates for toxicological studies on the level of the whole organism. Complementary, microscopic analyses at the individual particle level provide detailed information about which cells and subcellular components are the target of inhaled particles. These studies contribute to shed light on mechanisms and modes of action eventually leading to adverse health effects by inhaled nanoparticles. We review current methods for macroscopic and microscopic analyses of particle deposition, retention and clearance. Existing macroscopic knowledge on particle biokinetics and microscopic views on particle organ interactions are discussed comparing nanometer and micrometer sized particles. We emphasize the importance for quantitative analyses and the use of particle doses derived from real world exposures. INTRODUCTION It is expected that the use of nanomaterials and primarily of nanoparticulate materials will hold a key position in future science, technology and medicine. It spans from automotive, aircraft and space industry, to (bio)chemical and environmental engineering, to optics, electronics and communication technologies, to pharmacology and medicine, but also to day to day consumer products, i.e. to food, cosmetics and healthcare. The introduction of nanoparticulate materials is based on their exquisite properties and furthered by mandates of energy and resource savings. In this paper we will not focus on the manifold beneficial qualities of these new technologies but examine aspects of concern to pose risks for consumers and our societies. The exponentially increasing production of engineered nanoparticles urgently requires risk assessment of their potential for adverse health effects. Thereby, data for inhaled nanoparticles is particularly important because (i) this is the major route for unwanted exposure, and (ii) there is ample and consistent evidence for adverse health effects being associated with increased concentrations of ambient fine and ultrafine particles (e.g. [1-5]). Also, for nanoparticles with anticipated beneficial use, e.g. as diagnostic tools or therapeutics in medicine [6,7] health risk assessment is necessary. Even already tested materials have to be included since nanoparticles tend to have different properties compared to larger particles of the same material [8]. Risk assessment comprises exposure assessment, hazard identification and characterization, as well as risk characterization. The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) of the European Commission emphasized in its recent report on Risk Assessment of Products of Nanotechnologies [9] a number of critical factors for assessing the impact of nanoparticles and health: (i) so far, exposure assessment for existing nanomaterials is rudimentary. (ii) hazardous nanomaterials need to be characterized both "as manufactured" and in the various possible forms "as delivered" in bio- and eco-systems, (iii) the current lack of a generally applicable paradigm for nanomaterial hazard identification demands a case by case approach for the risk assessment of nanomaterials. Studies in humans or large animal species are limited; hence we have to resort to rodents to obtain sufficiently detailed data for risk assessment by inhaled particles [10]. The focus of this paper is hazard identification and characterization, which starts with dosimetry, i.e. the evaluation of the deposition pattern of inhaled particles and their subsequent dissemination (biokinetics) in the respiratory tract and the entire organism. Therein microscopic analyses at the individual particle level provide detailed information about which cells and subcellular components are targeted by inhaled particles. Such studies intend to convert external exposure to internal exposure or biologically effective dose, and may help to set limits in that way. We present and discuss primarily the results from studies we performed on the deposition, retention and clearance, as well as on secondary organ translocation of (insoluble) nanoparticles at a macroscopic and a microscopic level in view of contributing to nanoparticle characterization and identification of their potential risk. We compare data from inhaled nanoparticles (particles ≤ 100 nm in diameter) with those from micrometer-sized particles with diameters from 100 nm up to 10 μm. However, due to the blurred upper size limit of nanoparticles we consider micrometer-sized particles as those in the range of 0.5 - 10 μm. In addition, we include detailed methodological information allowing the application of protocols by the interested reader. METHODS Methods for macroscopic studies Quantitative biokinetics Quantitative biokinetics can be performed after nanoparticle administration by any route: by inhalation or intratracheal instillation to the respiratory tract, by gavage to the gastro-intestinal tract, by intravenous or intra-arterial injection to the blood circulation and by dermal applications to the skin. The concept is simple, aiming to estimate the total amount of nanoparticles in the entire body at a certain time point after exposure and in all excretions until this time point. Hence, not only the distribution of nanoparticles in organs and tissues of interest is assessed, but nanoparticles in the remaining carcass and those excreted are also included. With this, a 100% balance to the administered nanoparticles is achieved and a complete, yet detailed, quantitative analysis of their biokinetics is obtained [11,12]. For this purpose, particle distribution is measured at several time points after particle exposure, as shown in Figure 1. Although this approach is applicable to any animal species, ethical, economic and practical reasons restrict quantitative biokinetics to small laboratory animals. [Figure: Concept of quantitative nanoparticle biokinetics. Nanoparticles (NP) are administered at time t = 0. From this time point on, the entire urinary and fecal excretions are collected separately. Animals are euthanized at times t1, t2, t3, etc., and organs and tissues of interest as well as the entire remaining carcass are sampled (100% balanced sampling). Samples require special preparation before chemical analysis, e.g. by inductive-coupled-plasma mass spectroscopy (ICP-MS). When nanoparticles are radio-labeled, samples will be analyzed directly, without any further preparation. Reprinted with permission from [21].] Analytical chemistry e.g. inductively coupled plasma mass spectroscopy (ICP-MS) or atomic absorption mass spectroscopy (AA-MS) provides suitable methods to quantify particles in the collected specimens. Thereby, special attention has to be paid to sample preparation, i.e. when nanoparticles need to be dissolved, the extremely low content of ions resulting from the very low nanoparticle mass may lead to substantial ion loss to the walls of the reaction vessels prior to sample analysis. Radio-spectroscopy may provide an elegant alternative, allowing direct analysis of native organs and tissues without any pre-treatment. In this case, the radio-label needs to be firmly integrated into the nanoparticle matrix without any leaching. While this requirement is hard to fulfill, when a radio-isotope is blended into the nanoparticles during production, stable labeling is obtained, when the radio-isotope belongs to the same chemical element as the nanoparticle matrix. The latter, requiring integration of